Author: admin

Board Proposed NT$10 Cash Dividend Per Share

HONG KONG SAR – Media OutReach Newswire – 11 March 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for full year 2025 and provides 2026 outlook.

FY25 Business and Financial Highlights

• Company reported full year revenues, with discontinued operations reported separately, of NT$19,014 million, up 9.11% from the prior year and basic EPS of NT$23.90, or NT$2.63 for the fourth quarter. Full year EPS represents a 24.22% year-over-year decline, mostly due to a net loss per share of NT$11.24 from discontinued operations.
• In the fourth quarter, following the completion of tech transfer of production transitions out of the Plymouth area in Minnesota, the COGS of those originally Plymouth-made inventories have been reconsolidated to COGS line. Hence on a like-for-like basis when compared with other quarters in 2025, fourth quarter gross margin would have been approximately 38-39%. The reported high single-digit percentage sequential decline in gross margin, which also led to softened operational leverage, was primarily attributable to a temporary slowdown in DLS orders from following the entry of a new competitor in Nov. with limited launch visibility during the quarter. Higher effective tax rates during the quarter were a direct result of less sell-through downstream from related party transactions of the internally manufactured generic products. In addition, heightened generics competition of Topiramate ER, a leading generics product of Upsher-Smith, was also a negative gross margin mover.
• Management believes the 4Q25 OPEX profile more accurately reflects the expanded operating platform and our strategic repositioning into new focus areas. Sales and marketing expenses increased seasonally in line with market share cadence and channel expansion initiatives, while R&D spending sat on the disciplined side. Gross margin expansion serves as the key lever for operating leverage as scale improves fixed-cost absorption.
• Pharma sales revenue remained volatile in the fourth quarter as legacy inventory phased out and new product approvals remain pending. Generics portfolio competitiveness remains a key focus area in the near term for both top line and gross margin. Nevertheless, led by vigabatrin franchise, Bora’s rare disease portfolio continued to gain impressive market share across dosage forms. The Company aims to actively refill pipelines in 2026 to regain profitable growth.
• The Group’s CDMO business delivered another strong quarter in both revenues and gross margin. Supported by expanded capacity and the addition of new dosage forms, CDMO revenues grew 53.8% year-over-year in 2025 to NT$10.64 billion, including internal orders. Excluding internal orders, revenues reached NT$7.50 billion, representing a 19.53% increase compared to 2024.
• As 2025 marked a year of post-merger integration and strategic consolidation, Bora achieved its highest operating cash flow margin in recent years at 34.74% in the fourth quarter, compared with -4.00% in the same period last year. This improvement reflects the transformation of the Bora Group into a more efficient organization operating on a larger and stronger platform. The Board has proposed a NT$10 cash dividend per share, demonstrating confidence in the Group’s strengthened cash generation and commitment to delivering sustainable returns to shareholders, reaching the highest yield rate proposed.
• Share capital increased 3.18% during the quarter from employee stock option exercise and convertible bond conversions.

Mr. Bobby Sheng, Chairman of Bora Group, stated, “2025 represented a pivotal year for Bora Group. Beyond post-acquisition integration, it was a year of disciplined capital allocation and balance sheet stewardship. Having stepped onto a larger growth platform, we deliberately reassessed optimal cash deployment, portfolio mix of both CDMO and Pharma Sales businesses and forthcoming return metrics under a stable equity structure. One year after closing the 2024 acquisitions, we achieved our highest operating cash flow margin, marking a complete turnaround from the same period last year when the Group first transitioned to its current scale.

The external environment was marked by significant shifts. We operated against a backdrop of renewed U.S. trade and industrial policy shifts, triggering supply chain realignment and foreign exchange fluctuations. At the same time, rapid AI adoption began reshaping manufacturing competitive dynamics, if not capital market funding flow. Concurrently, the Group faced competition in a handful core generic products that remain meaningful contributors to revenue and EBITDA. Discontinued operations aside, based on the reclassified financial statements for 2025 and 2024, EBITDA for continued operations declined 19.0% compared to 2024, but remains 12.5% higher than 2023, underscoring the structurally higher revenues and earnings base established over the past 2 years.

Despite these headwinds, the Group remained profitable and has preserved financial flexibility. Notably, we funded Bora’s largest CDMO CAPEX program in our history and executed the business transformation of Upsher-Smith entirely within existing credit facilities, without incremental equity dilution. While value expansion of this new Bora Group platform took longer than the Company expected, we believe the year demonstrates the resilience of our operating model, disciplined financial management, and our ability to execute strategic investments while maintaining earnings and balance sheet integrity.

We are especially delighted to share the contract renewal with GSK earlier this year. From day one, this partnership was built on mutual trust and a shared commitment to quality. With the latest developments, we are looking at a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability. We have also established new partnerships with several high-growth pharmaceuticals over the past few months, further expanding our client base across our North American network. These partners share our belief in an integrated and orchestrated supply chain model, leveraging our multi-site platform to support development, manufacturing, and commercialization needs.

To sum up, the CDMO rolling 12-month external order backlog, after a good quarter of digestion and less working days, arrived at US$264 million. Total external wins in 2025 reached a phenomenal US$482 million, of which 89% were commercial-stage orders and 16 molecules in pre-commercial stage, providing solid visibility into 2026 and beyond especially for Canada and Baltimore sites. At the same time, Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio.

On the pharma sales side, Upsher-Smith today represents a structurally repositioned platform. Performance has been increasingly driven by lifecycle management, including continued maximization of the infantile spasm franchise, alongside active pipeline replenishment with a heightened focus on differentiated assets, particularly NCEs in rare diseases. Within Generics, we have confirmed 7 launches in 2026, including the recently approved Cyclosporine and an in-licensed product indicated for hyponatremia. We are also observing a more constructive environment for DLS than initially anticipated, with 2026 year-to-date market share maintained. Last but not least, based on our current knowledge of the relevant U.S. patent rulings, if TWi receives approval for Cladribine (gMavenclad), Upsher-Smith, as the exclusive distributor, would be positioned to launch the product in the U.S., subject to customary regulatory and commercial considerations.

Beyond our base expectation of launching more than 10 generic products annually, we have identified revenue and EBITDA accretive, bolt-on investment opportunities to further strengthen this business in 2026. These include progressively expanding our injectable and 505(b)(2) portfolios to enhance differentiation and economics, as well as deepening penetration across proprietary and specialty distribution channels. When we exit this year with a more diversified and better-calibrated product mix, we expect improved earnings resilience and more stable growth trajectory going forward.”

FY25 Operational Achievements & 2026 Outlook

Global CDMO Operations

Global CDMO operations revenue reached record highs for both the quarter and the full year, accounting for approximately 45.78% of reported revenues in the quarter and 39.43% for FY2025. In total, 2.5 billion doses were developed and manufactured. Revenue contribution from the top 20 global pharmaceutical companies declined slightly to 29% from the low-30% range previously, primarily reflecting the addition of several fast-growing pharmaceutical clients to the Company’s portfolio in recent years, with increasing contributions from their successful product launches.

As the Company continues to expand its CDMO capacity and capabilities, including approximately 10% additional aseptic fill/finish capacity and a net ~3% expansion in solid and liquid dosage capacity, Bora Group monitors utilization rate carefully across facilities. While the Company remains confident that investing in U.S. manufacturing capacity is strategically sound, given the importance of the U.S. pharmaceutical market and supply chain resilience, capital allocation must also align with prevailing industry investment cycles. Against this backdrop, a structural supply gap in single-use drug substance (DS) bioreactor capacity, projected to grow at an estimated 8–10% CAGR, reinforces the rationale for continued investment in Tanvex Biopharma (branded as Bora Biologics) as Bora Group expands its CDMO platform. Supported by a more favorable funding environment for early-stage biotech companies in the US, rapidly growing biologics pipeline, increasing FDA approvals, long product lifecycles, and Tanvex’s integrated access to Bora’ Group’s drug product (DP) fill/finish capabilities, the strategic platform presents a compelling long-term value creation opportunity. While this represents a near-term drag on reported earnings, the Company believes these investments are necessary to position Bora Group for long-term participation in the CDMO market that values quality and OTIF (On Time, In Full) delivery.

Pharma Sales Operations

Pharma Sales operations generated revenue of NT$2.64 billion in the fourth quarter, marking one of slowest quarters since the Upsher-Smith merger. For the full year, Pharma Sales declined 11.30% compared to 2024, excluding the impact of discontinued operations related to delisted products, and accounted for 60.48% of total revenues.

A key leading indicator in specialty pharma is the number of new patients, and across the Vigabatrin franchise, Upsher-Smith continues to demonstrate positive momentum on this front. Upsher-Smith intends to pursue enhanced customer segmentation to further increase salesforce effectiveness in 2026 with investments in key commercial functions and patient access to increase salesforce effectiveness.

Recent Investor Conference

Bora will host an English online earnings call at 9:30 p.m. Taiwan time on Mar. 12^th, 2026, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:00 p.m. on Mar. 19^th, 2026. Both events will cover the Company’s 2025 financial and business results and 2026 outlook.

English Online Earnings Presentation Link: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5255333/bora-pharmaceuticals-otcqx-boray-twse-6472

Bora will participate in 2026 Jefferies Asia Forum in March in Hong Kong and an East coast NDR in NYC and Boston. For 1:1 meetings with management, please contact your Jefferies and Sinopac representative.

Bora 2026 Earnings Schedule

Q1 2026: Expected in the 2^nd week of May 2026
Q2 2026: Expected in the 2^nd week of Aug 2026
Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #Bora

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

創下2020年以來最健康營運現金流利潤率 雙引擎平台基底更紮實 支撐2026年補強型投資拚重返增長、再上一階 董事會擬配發每股新台幣10元現金股利

香港 – Media OutReach Newswire – 2026年3月11日 – 全球領先的CDMO及專科製藥公司——保瑞藥業股份有限公司（Bora Pharmaceuticals，「保瑞」；TWSE：6472；OTCQX：BORAY）今日公布2025年全年財務成果與營運亮點，並提供2026年展望。

2025年全年營運與財務重點：

• 公司2025年全年營收（停業部門另列）為新台幣190.14億元，較前一年成長9.11%；基本每股盈餘（EPS）為23.90元，其中第四季EPS為2.63元。全年EPS較去年下降24.22%，為停業部門每股淨損11.24元所致。
• 在第四季，隨著美國明尼蘇達州廠區之Plymouth區域將部份Upsher-Smith自有產品之生產轉移的技術轉移工作完成，原由Plymouth生產的產品重新歸入銷貨成本（COGS）。因此，以可比基礎與2025年其他季度相比，第四季毛利率約為38–39%。第四季毛利率較前一季下降並導致營運槓桿減弱，主係胃食道逆流藥物DLS於11月面臨新競爭者，下游拉貨動能轉為觀望、放緩。此外，當季較高的有效稅率亦來自自製的學名藥DLS透過關係人交易後面臨下游銷售量減少使得營收與稅負無法同步。同時，Upsher-Smith的主要學名藥產品Topiramate ER面臨更激烈的市場競爭，也對毛利率造成負面影響。
• 管理層認為，2025年第四季的營運費用結構更能反映公司此階段的營運平台模式與策略轉型。推銷費用隨著市場占有率推進與通路拓展而呈現季節性上升，而研發支出則維持在相對審慎的範圍內。隨著規模擴大帶來固定成本吸收能力提升，毛利率的改善將成為推動營運槓桿的關鍵因素。
• 全球藥品銷售業務在第四季仍有不小的波動，主因仍在等待新產品核准，無法填補下市產品與漸失動能的既有產品下滑。短期內，提升學名藥產品組合競爭力是公司在營收與毛利率上的重要課題。不過公司對轉型進展並不悲觀，在Vigabatrin系列產品帶動下，保瑞罕病產品組合在各劑型市場占有率持續提升。公司將於2026年積極補充在研與新上市產品，以恢復獲利性成長。
• 集團CDMO業務在第四季營收與毛利率雙升。受惠於產能擴張及新劑型導入，2025年CDMO營收含內部訂單年增53.8%，達新台幣106.4億元。若排除內部訂單，營收為新台幣75億元，較2024年成長19.53%。
• 2025年是保瑞併購後整合與策略整併的一年。第四季營運現金流利潤率達34.74%，創近年新高，相較去年同期為-4.00%，此改善反映保瑞集團已轉型為一可在更大且更強的平台上運作、效率更高的組織。董事會提議配發每股新台幣10元現金股利，展現對集團現金創造能力提升及長期股東報酬的信心。
• 本季因員工認股權行使及可轉債轉換，股本增加3.18%。

保瑞集團董事長盛保熙表示：「2025年對保瑞而言是具有轉折意義的一年。除了整合外，我們更加強調紀律性資本配置與資產負債表管理。在站上更大的成長平台後，我們重新檢視現金部署方式、雙引擎業務細部的技術與產品組合，並且定義在穩定股權結構下，未來應觀察的報酬指標。距離2024年併購完成一年後，我們實現了歷史最高的營運現金流利潤率，相較去年同期集團剛轉型至目前規模時呈現明顯翻轉。

然而，外部環境出現重大變化。我們在美國貿易與產業政策重新調整的背景下營運，這也促使供應鏈重新配置並帶來匯率波動。同時人工智慧的快速導入正在改變製造業競爭格局，甚至影響資本市場資金流向。此外，集團部分核心學名藥產品也面臨競爭壓力。若排除停業部門影響，依據2025與2024年重分類後的財務報表，繼續營運單位EBITDA較2024年下降19.0%，但仍較2023年高出12.5%，顯示過去兩年所建立的營收與獲利基礎仍然穩固。

儘管面臨這些挑戰，集團仍維持獲利並保有財務彈性。值得注意的是，我們在未新增股權稀釋的情況下，透過既有信用額度完成保瑞歷史上最大規模的CDMO資本支出計畫與Upsher-Smith的業務轉型。雖然這個新平台的價值擴張醞釀較公司原先預期稍長，但這一年也展現了我們營運模式的韌性、有紀律的財務管理，以及在維持獲利與資產負債表穩健的同時推動策略投資的能力。

我們也非常高興今年稍早與GSK完成續約。自合作開始以來，這段夥伴關係一直建立在互信與對品質的共同承諾之上。隨著最新合作進展，我們將與GSK邁向十年的合作關係，展現雙方皆相當重視可靠的供應鏈。我們在過去幾個月也與多家成長快速的製藥公司建立新的合作關係，進一步擴展北美CDMO網絡的客戶基礎。

總結而言，CDMO業務的未來12個月在手訂單在經歷一個季度的消化及第四季工作天數較少影響來到2.64億美元。2025年新簽訂單達4.82億美元，其中89%為商業化階段訂單，另有16個分子處於研發階段，為2026年起的營收提供良好能見度，特別是在加拿大與馬里蘭針劑廠。

在全球銷售業務方面，Upsher-Smith目前儼然是一個嶄新的組織。其業績愈來愈由產品生命週期管理所驅動，包括持續最大化嬰兒痙攣產品線的價值，同時積極補充在研與新上市產品，並特別聚焦於罕病領域的差異化品項與新藥銷售機會。在學名藥方面，我們已確認2026年將上市7項產品，包括近期核准的用於乾眼症的Cyclosporine以及一項治療低鈉血症的授權產品。

此外，根據我們目前對美國相關專利判決的理解，若保盛藥業取得原廠為默克Mavenclad的Cladribine學名藥核准，Upsher-Smith作為獨家經銷商將有機會在符合相關法規與商業條件下於美國市場準備產品上市。

除了每年推出超過10項學名藥產品以重啟增長的基礎目標外，我們也已辨識出多項能夠提升營收與EBITDA的補充型投資機會，以進一步強化2026年的業務基礎，包括逐步擴大注射劑與505(b)(2)產品組合，提升產品差異化與經濟效益，同時深化專利產品與專科通路的滲透率。我們期許在今年結束時，集團的產品組合更加多元且平衡，預期未來獲利韌性將提高，成長軌跡也將更為穩定。」

2025年全年營運成果暨2026年展望

業務進展說明：

• 全球委託研發暨代工製造服務(Global CDMO Operations)業務當季與全年皆創下營收新高：
  第四季CDMO營收占總營收約45.78%，2025年全年占比為39.43%。全年共開發與製造25億劑藥品。前20大全球製藥公司的營收貢獻比例略降至29%，過去則維持在微幅超過30%區間，主要反映新增多家快速成長的製藥客戶加入公司客戶組合，且其成功上市產品的貢獻逐步提升。

  隨著公司持續擴充 CDMO 產能與能力，包括約10%的無菌充填產能提升以及固體與液體劑型合計約3%的淨擴張，保瑞集團持續關注各廠的產能利用率。著眼於美國製藥市場的重要性以及供應鏈韌性的考量，公司相信在美國投資製造能力是正確的策略，惟資本配置需要反映當前產業投資週期。

  評估市場需求，北美持續浮現一次性生物反應器在大分子原料藥（DS）產能的缺口，又受惠於快速增加的生物藥開發管線，總體生物製劑市場將以約 8–10% 的年複合成長率擴張，保瑞集團持續看好DS CDMO在美國生物醫藥募資環境好轉，特別是具備臨床數據支持以及抗體藥物複合體（ADC）領域的早期生物製劑市場高速成長、產品生命週期較長，且對供應鏈黏著度高的特性，認為目前北美具生產彈性的一次性生物反應器產能屬稀缺資源，泰福旗下大分子CDMO平台在完成擴產後將能更好地回應美國市場對單次使用生物反應槽的強勁需求，即便短期內泰福將持續對保瑞業外表現帶來壓力，仍是保瑞集團一站式CDMO服務中未來成長最關鍵的一塊。
  

• 全球市場銷售(Global Commercial Operations)業務第四季營收為新台幣26.4億元，為Upsher-Smith併購後較為疲弱的季度之一：

  2025年全年營收較2024年下降11.30%，若排除因產品下市而列為停業部門的影響，全球銷售占公司總營收60.48%。

  在專科用藥領域中，新病患數是一項重要的領先指標。Upsher-Smith的Vigabatrin 系列產品在此指標上持續正向發展。2026年，我們計畫透過強化客戶分群策略，持續投資於關鍵職能與病患可近性（patient access）專案，以進一步提升銷售團隊的整體效率。

年度營運報告及法說會資訊

保瑞將在台灣時間3月12日晚間9:30參加美國OTC Markets Group舉辦之英文線上業績發表會，以及於3月19日下午2:00受邀參加台新證券假晶華酒店舉辦之業績發表會，向投資人說明公司2025年財務與業務報告及展望。

英文線上業績發表會連結：https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5255333/bora-pharmaceuticals-otcqx-boray-twse-6472

保瑞將於2026年3月前往香港參加2026 Jefferies Asia Forum 並於3月24日起於美國東岸紐約與波士頓進行NDR，若您希望與管理層面對面會議請聯繫您Jefferies與永豐業務。

保瑞2026年業績報告行事曆
2026年第1季：預計2026年5月第二周
2026年第2季：預計2026年8月第二周
2026年第3季：預計2026年11月第二周
2026年第4季：預計2027年3月第二周

Hashtag: #保瑞

The issuer is solely responsible for the content of this announcement.

關於保瑞

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：企業網站 https://www.bora-corp.com

免責聲明：
本文件及同時發佈之相關資訊內可能含有預測性敘述。除針對已發生之事實，所有對於本公司未來營運業務、可能發生之事件及展望（包括但不限於預測、目標、估算及營運計畫）之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性之影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市佔率、市場競爭情況、法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責任。

HANOI, VIETNAM – Media OutReach Newswire – 11 March 2026 – VinEnergo Energy Joint Stock Company, a subsidiary of Vingroup, and GE Vernova in the United States have officially signed a technology selection agreement to supply some of the world’s most advanced gas turbines and generators for VinEnergo’s LNG power plant project in Hai Phong. The event marks an important milestone in realizing the goal of developing VinEnergo Hai Phong into the largest gas-fired power plant in Vietnam, contributing to national energy security and promoting the transition toward a green economy.

The signing ceremony between VinEnergo and GE Vernova took place during The Energy of Change Summit 2026 in Hanoi, attended by Acting Minister of Industry and Trade Le Manh Hung and more than 400 reputable organizations from the global energy sector. The agreement represents a significant step toward ensuring construction progress and bringing the Hai Phong LNG power plant into operation by the end of 2030.

As a global leader in energy technology with more than 100 years of experience and a strong track record in meeting stringent environmental and operational standards, GE Vernova has been selected by VinEnergo as the core equipment supplier for the Hai Phong LNG power plant. Under the agreement, GE Vernova shall supply two 9HA.02 gas turbines and two H78 generators in phase I, with a capacity of 1600 MW, to ensure the plant can begin operations by the end of 2030.

Nguyen Anh Khoa, Chief Executive Officer of VinEnergo, stated: “Partnering with GE Vernova, a leading global supplier, to deploy the most advanced technologies will not only ensure optimal operational efficiency for the Hai Phong LNG power plant, but also reaffirm our strong commitment to pioneering emissions reduction and building a sustainable green industrial and energy ecosystem.”

Ramesh Singaram, President & CEO, Gas Power, Asia, GE Vernova stated: “We are honoured that VinEnergo and Vingroup have entrusted GE Vernova with a central role in this important project. Through the deployment of the 9HA.02 gas turbine and H78 generator, we are delivering advanced technology that supports lower emissions, industry‑leading efficiency, and reliable large‑scale power generation. This collaboration underscores our commitment to sustainable energy solutions and to supporting Vietnam’s accelerated transition to more sustainable energy.”

The GE Vernova 9HA.02 gas turbine technology is highly efficient, featuring fast startup capabilities and flexible load adjustment, allowing it to respond effectively to continuously fluctuating power demand. With combustion temperatures exceeding 1,400 degrees Celsius, the system significantly enhances power generation efficiency. Notably, the 9HA.02 turbine offers flexible fuel options, capable of burning hydrogen at up to 50% by volume, with a roadmap toward 100% hydrogen in the future, clearly demonstrating its alignment with sustainable energy development goals.

With the official signing of the cooperation agreement between VinEnergo and GE Vernova, the Hai Phong LNG power plant project, developed by a consortium of Vingroup and VinEnergo Energy Joint Stock Company, is expected to begin operations by the end of 2030 as planned and become one of the world’s leading LNG-fueled power plants.

Hashtag: #VinEnergo

The issuer is solely responsible for the content of this announcement.

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 11 March 2026 – Comfort is set to be a defining theme for Raya 2026, and it extends well beyond the festive outfit. XIXILI is bringing that same ease into the downtime between celebrations, with sleepwear designed for the hours when women can finally catch their breath, rest, and simply be.

The Reality of the Raya Rush

The lead-up to Raya is a whirlwind of grocery runs, deep cleaning, and late nights in the kitchen. By the time the first open house begins, most women have already put in an incredible amount of effort for their families. The quiet moments in between are not just a break. They are earned.

XIXILI’s pajamas are made for those moments. Easy to move in, soft enough to wear through the night, and the kind of pieces that make coming home feel like something to look forward to. Designed to fit a wide range of body types, every woman can find something that feels as good as it looks.

“Raya is everything. The food, the family, the laughter. And at the end of it all, she deserves to rest just as well as she celebrated,” says Tara Tan, Marketing Director at XIXILI.

Comfort That Carries Through the Season

Raya may bring the occasion, but the shift happening in Malaysian wardrobes goes further than that. Women are increasingly treating sleepwear as a considered part of their self-care, not just something to change into before bed.

“We often talk about the joy of gathering, but we rarely talk about the exhaustion that comes with it,” Tara Tan adds. “Our goal for Raya 2026 is to ensure that when the last guest leaves, every woman has a high-quality piece of loungewear to retreat into. It is about honouring the work she does by giving her the rest she deserves.”

Quality loungewear for the wind-down, the slow morning, and every quiet moment in between has become one of the most considered purchases a woman makes this season.

Made to Be Worn, Not Just Owned

Good sleepwear should not sit tucked away at the back of a drawer. It should be the first thing she reaches for at the end of a long day, worn in and looked forward to. XIXILI’s range is built for exactly that, styles that settle naturally into her routine and carry her well beyond the festive season.

The full sleepwear collection is available online and at XIXILI boutiques nationwide. To shop the range, visit www.xixili-intimates.com.Hashtag: #XIXILI

https://www.xixili-intimates.com/my/
https://www.facebook.com/XIXILI.OfficialFanPage/
https://www.instagram.com/xixili_intima/
https://www.tiktok.com/@xixili_intima?
https://www.youtube.com/user/xixilipage

The issuer is solely responsible for the content of this announcement.

About XIXILI

A homegrown Malaysian brand, XIXILI offers beautiful fashion lingerie and shapewear in Malaysia that prioritises fit and comfort. With an extensive range of bra sizes from A to I and bands 65 to 110cm, XIXILI caters to women of all shapes and sizes. Expert fitters are dedicated to helping each customer find the perfect bra, boosting confidence and enhancing silhouettes.

XIXILI became the first Malaysian lingerie brand to introduce a Try-On in 3D avatar tool, allowing customers to virtually try on XIXILI lingerie using a 3D avatar tailored to their specific body type and measurements. Whether for everyday wear or something special, XIXILI ensures women always look and feel amazing.

ジャカルタ、インドネシア – Media OutReach Newswire – 2026年3月11日 – 日本のエネルギー企業との対話で森林ガバナンスおよびトレーサビリティ制度を強調ジャカルタ — インドネシア共和国林業省は3月4日（水）、東京ガス株式会社および阪和興業株式会社の代表団との会合を林業省庁舎にて開催し、持続可能な森林ガバナンスおよび透明性の高いサプライチェーンの確立に向けた同国の取り組みを改めて強調した。

本会合は、持続可能な森林経営に関する理解の深化および、バイオマス分野を含むインドネシアの森林関連産業を支えるガバナンス枠組みに対する相互理解の強化を目的とした、国際パートナーとの継続的な対話の一環として開催されたものである。

インドネシア林業省 森林産品加工・マーケティング開発局長のアデ・ムカディ氏は、インドネシアが森林資源の利用を国家規制および持続可能性原則に基づき責任ある形で実施するため、森林ガバナンス体制の強化を継続していることを強調した。

同氏は次のように述べた。
「インドネシアは、合法性保証、持続可能性基準、そして独立した検証制度を統合した包括的な森林ガバナンスの枠組みを構築しています。私たちは引き続きこの制度の強化を進め、透明性、説明責任、そしてサプライチェーンの信頼性を確保していきます。」

東京ガスおよび阪和興業は、ゴロンタロ州ポフワト県において事業を展開するPT Biomasa Jaya Abadi（PT BJA）が生産する木質ペレットの購入企業である。

林業省 森林産品認証・マーケティング課長のトニー・リアント氏は、インドネシアの森林ガバナンス制度が以下の四つの柱に基づいていると説明した。すなわち、生態系・社会・経済のバランスを確保する持続可能な森林経営、透明性および説明責任、規制遵守、そして先住民族および地域社会の権利尊重である。

この枠組みの中核を成すのが、インドネシアの「木材合法性および持続可能性検証制度（SVLK）」である。同制度は、森林産品が合法かつ持続可能に管理された森林から生産されていることを保証する国家的な認証制度である。

SVLKは、伐採、輸送、加工、輸出に至るサプライチェーン全体を対象としており、森林事業者、産業事業者、および輸出事業者を監査するために認定された独立検証機関によって実施されている。

また、インドネシア政府は、国際市場の要求の変化に対応するため、制度のさらなる高度化を進めている。これには、伐採地点におけるジオロケーションベースのモニタリングの導入や、輸送および輸出関連書類のデジタル化などが含まれる。これらの取り組みは、トレーサビリティの強化およびEU森林破壊防止規則（EUDR）などの新たな国際的デューデリジェンス要件への対応を支援することを目的としている。

会合ではまた、インドネシアの森林利用計画制度についても議論が行われた。これには、長期森林経営計画に基づく伐採活動を規定する「年次作業計画（RKT）」が含まれ、生物多様性保全および環境保護措置が組み込まれている。

林業省は、森林利用活動が厳格な規制監督およびモニタリング体制の下で実施されており、環境保護措置および持続可能な森林経営の確実な履行が確保されていることを改めて強調した。

なお、本会合は、東京ガスおよび阪和が3月2日（月）にポフワト県政府と行った協議に続くものである。サイフル・A・ムインガ県知事は、PT BJAがすべての許認可要件を満たし、合法的に事業を運営していること、さらに1,500人以上の雇用を創出することで地域経済に貢献していることを確認した。

PT BJAを含むポフワト県への投資は、地域経済成長率を約9％押し上げており、地方政府は同地域における投資活動に対して厳格な監督を継続している。

Hashtag: #TirtoIndonesia

The issuer is solely responsible for the content of this announcement.

JAKARTA, INDONESIA – Media OutReach Newswire – 11 March 2026 – The Ministry of Forestry of the Republic of Indonesia reaffirmed the country‘s commitment to sustainable forest governance and transparent supply chains during a meeting with representatives from Tokyo Gas Co., Ltd. and Hanwa Co., Ltd. at the Ministry‘s office on Wednesday (March 4).

The meeting was part of Indonesia‘s ongoing engagement with international partners to strengthen mutual understanding of sustainable forest management and the governance framework underpinning Indonesia‘s forest-based industries, including the emerging biomass sector.

Ade Mukadi, Director of Forest Product Processing and Marketing Development at the Ministry of Forestry, emphasized that Indonesia continues to strengthen its forest governance architecture to ensure that forest utilization is conducted responsibly and in accordance with national regulations and sustainability principles.

“Indonesia has established a comprehensive forest governance framework that integrates legality assurance, sustainability standards, and independent verification. We continue to enhance this system to ensure transparency, accountability, and supply chain integrity,” Ade stated.

Tokyo Gas and Hanwa are buyers of wood pellets produced by PT Biomasa Jaya Abadi (PT BJA), which operates in Pohuwato Regency, Gorontalo Province. Tony Rianto, Head of the Sub-Directorate for Forest Product Certification and Marketing, explained that Indonesia‘s forest governance system is guided by four key pillars: sustainable forest management that balances ecological, social, and economic functions; transparency and accountability; regulatory compliance; and respect for indigenous peoples and local communities.

Central to this framework is Indonesia‘s Timber Legality and Sustainability Verification System (SVLK), a national assurance system ensuring that forest products originate from legal and sustainably managed sources. The system covers the entire supply chain—from harvesting and transportation to processing and export—and is implemented through independent verification bodies accredited to audit forest operators, industries, and exporters.

Furthermore, Indonesia continues to enhance the system in line with evolving global market expectations, including the development of geolocation-based monitoring at harvesting sites and the digitalization of transport and export documentation.

These measures are designed to strengthen traceability and support compliance with emerging international due diligence requirements, such as the European Union Deforestation Regulation (EUDR).

During the meeting, discussions also covered Indonesia‘s forest utilization planning framework, including the Annual Work Plan (RKT), which regulates harvesting activities under approved long-term forest management plans and incorporates biodiversity safeguards and conservation measures.

The Ministry reaffirmed that forest utilization activities are subject to rigorous regulatory oversight and monitoring mechanisms to ensure compliance with environmental safeguards and sustainable forest management practices.

The meeting followed an earlier discussion between Tokyo Gas and Hanwa and the Pohuwato Regency Government on Monday (March 2). Regent Syaiful A.

Mbuinga confirmed that PT BJA has fulfilled all licensing requirements, operates legally, and contributes to the local economy by employing more than 1,500 workers.

Investment in Pohuwato, including from PT BJA, has contributed to regional economic growth of around 9%, with the local government maintaining strict oversight of investment activities in the region.

Hashtag: #TirtoIndonesia

The issuer is solely responsible for the content of this announcement.

HANOI, VIETNAM – Media OutReach Newswire – 10 March 2026 – Amid volatility in global fuel prices, Vingroup has announced the launch of a special “Trade Gas for Electric” program in Vietnam, India, Indonesia, and the Philippines. The program offers an additional 3% discount on VinFast cars and 5% discount on VinFast electric scooters for customers switching from old gasoline vehicles. At the same time, fares for Xanh SM services will be reduced by 10% from March 11 to March 31, 2026, depending on each market.

Specifically, in addition to the existing incentives currently available, customers who switch from old gasoline vehicles to new VinFast electric vehicles during the program period will receive an additional 3% discount for cars and 5% discount for scooters. The program will be applied across all four markets: Vietnam, India, Indonesia, and the Philippines.

In line with VinFast’s pioneering spirit, GSM Green and Smart Mobility Joint Stock Company has also announced an immediate 10% reduction in fares for electric mobility services on the Xanh SM platform in Vietnam and Green SM in Indonesia from March 11 to March 31, 2026. This initiative offers customers a more environmentally-friendly and cost-effective transportation option.

The program may be extended depending on international developments and future fuel price movements.

Ms. Duong Thi Thu Trang, Deputy CEO of Global Sales, VinFast, stated: “The special ‘Trade Gas for Electric’ program launched in March across four key markets is VinFast’s timely response to geopolitical volatility that is affecting socio-economic conditions in many countries around the world. As one of the pioneering manufacturers leading the global electric vehicle revolution, VinFast together with companies in Vingroup’s green ecosystem aims to help reduce the impact of fuel prices on people’s daily lives while also lowering environmental pollution through smarter, more sustainable, and more cost-efficient mobility solutions.”

The special “Trade Gas for Electric” program will be implemented in parallel with and combined with other available incentive programs in each market. Through layered incentives, Vingroup and companies within its ecosystem aim to create favorable conditions for customers to transition quickly to electric vehicles, reduce dependence on gasoline, stabilize daily life, and contribute to building a cleaner and more civilized living environment.

Hashtag: #Vingroup

The issuer is solely responsible for the content of this announcement.

New Academy and Shenyang satellite office strengthen SUSS’ visibility and partnerships across Western and Northeast China.

CHONGQING, CHINA – Media OutReach Newswire – 10 March 2026 – The Singapore University of Social Sciences (SUSS) today launched the SUSS Success Academy in Chongqing in collaboration with Raffles Young Academy (RYA) Pte Ltd and announced the establishment of a satellite office in Shenyang. Building on its Success Academies in Beijing and Shenzhen, the Academy strengthens SUSS’ presence in China and supports its growing engagement across Western and Northeast China.

The launch was commemorated with an opening ceremony at the CCI Gallery, attended by close to 70 guests from China and Singapore, including representatives from institutions of higher learning, and industry and community partners. The ceremony was presided by Vice-Consul (Political) Ms. Mavis Tan, Consulate-General of the Republic of Singapore, Chengdu and Mr. Li Xunfu, Deputy Director of Chongqing Municipal Commission of Commerce.

Success Academy to connect partners from Singapore and China

Anchored in SUSS’ commitment to lifelong learning and creating social impact, the Academy will serve as a key nexus for academic and industry partners from both countries. Through cross-cultural collaboration and practice-oriented learning, it also aims to develop future-ready talent equipped to contribute meaningfully to society and the economy.

RYA is an education and talent development organisation aimed at nurturing future-ready talent through industry-oriented learning and international exposure. RYA will bring its networks and local expertise to support and enhance the Academy’s initiatives.

Through the Academy, SUSS will provide opportunities for students from SUSS and other Singapore pre-tertiary and tertiary institutions to co-learn and co-innovate with peers in China. These include interdisciplinary global learning courses, impact startup and venture builder programmes, industry-based immersions and student exchanges. SUSS students will also gain regional exposure through internships and other workplace learning opportunities. In addition, the Academy will support SUSS in working with universities and organisations in China to jointly design and deliver industry-relevant courses and programmes for students and executives.

Extending engagement into Northeast China with Shenyang satellite office

To further deepen its engagement in Northeast China, SUSS will launch a satellite office in Shenyang on 11 March 2026 under the Success Academy in Chongqing. This office will support SUSS’ initiatives in Liaoning Province and surrounding areas, including Dalian. In addition, three Memoranda of Understanding (MOU) will be signed with the following organisations:

• Shenyang University of Chemical Technology (SYUCT): Collaborative development of a Master’s degree programme in Social Work, fostering cross-border knowledge exchange, curriculum innovation, and talent development to address evolving social service needs.
• North-East Institute of Population and Social Development: Joint research endeavours, professional development programmes, and meaningful academia-industry partnerships to generate evidence-based solutions, build capabilities, and promote active ageing ecosystems that benefit individuals and communities.

Professor Tan Tai Yong, President of SUSS, said, “China is an important partner for SUSS as we expand opportunities for our students and strengthen collaboration across Asia. The launch of the Success Academy in Chongqing allows us to work more closely with universities, industry and community partners in Western and Northeast China, and to deliver applied, practice-oriented education that responds to real-world needs. Our partnership with Raffles Young Academy reflects our shared commitment to developing future-ready talent and supporting professional growth across the region.”

Mr. Samuel Ng, Executive Chairman, RYA, said, “Our collaboration with the Singapore University of Social Sciences reflects a shared belief in applied, practice-oriented education and in preparing students and enterprises to navigate an increasingly complex and interconnected world. Chongqing’s strategic position as a gateway to Western China and a hub for industry and connectivity makes it an ideal location for immersive, industry-linked education. This partnership represents a long-term commitment to building enduring bridges between students and industry, between academia and practice, and between Singapore and China.”

The launch of the Success Academy in Chongqing is part of SUSS’ broader expansion across Asia. Since 2023, SUSS has established Success Academies in Beijing, Shenzhen, Ho Chi Minh City Bangkok, Kuala Lumpur, Jakarta, Manila and Mumbai.

For more information, visit www.suss.edu.sg/success-academy.
Hashtag: #SUSS

https://www.suss.edu.sg
https://www.linkedin.com/school/singapore-university-of-social-sciences
https://www.facebook.com/suss.sg
https://www.instagram.com/suss.sg

The issuer is solely responsible for the content of this announcement.

落子重庆，辐射西部，联动沈阳——新加坡社科大学通过设立“成就学院”及沈阳办事处，精准拓展在华战略布局，全面提升在中国西部及东北地区的知名度与合作伙伴关系。

中国重庆 – Media OutReach Newswire – 2026年3月10日 – 新加坡社科大学（SUSS）今日在渝宣布两项重大战略举措：正式携手莱福士教育（RYA）成立新加坡社科大学成就学院，并同步宣布设立沈阳卫星办事处。

此举标志着新加坡社科大学在中国市场的深耕迈入新阶段。新设立的成就学院，将与既有的北京、深圳成功学院形成合力，进一步完善SUSS在华网络。通过重庆这一西部重镇和沈阳这一东北枢纽，大学将精准对接区域需求，深化拓展在中国西部及东北地区的合作伙伴关系，提升学术影响力与品牌知名度。

庆典仪式在重庆市中新互联互通项目展厅(CCI)隆重举行，吸引了近70位中新两国嘉宾出席，包括高等院校代表、行业领袖及社区合作伙伴。新加坡驻成都总领事馆副领事（政务）陈诗惠女士，重庆市商务委员会副主任李巡府先生，及重庆市渝中区委常委、区政府常务副区长邓光怀先生共同主持仪式。

成就学院：搭建新中合作新桥梁

成就学院立足于新加坡社科大学对终身学习与社会影响力的坚定承诺，致力于打造连接新中两国学术界与产业界的关键枢纽。

学院将通过跨文化协作与实践导向的学习模式，着力培养能够为社会发展与经济进步做出实质性贡献的未来型人才，为两国伙伴关系注入持久活力。

作为专注教育与人才培养的机构，莱福士教育致力于通过行业导向的学习模式与国际化的教育视野，培养具备全球竞争力的未来型人才。学校将充分发挥其本土资源网络与专业优势，为成就学院的各项举措提供坚实支持与协同助力。

成就学院将打造一个全新的中新教育协作平台，为新加坡社科大学及新加坡其他中小学、高等院校学生提供与中国学子协同学习、共同创新的宝贵机会。合作项目涵盖跨学科全球学习课程、影响力创业孵化计划、产业深度实践及学生交流项目。

依托这一平台，新加坡社科大学学生可通过实习等职场学习机会，深入拓展区域视野，积累实践经验。与此同时，成就学院还将积极协助新加坡社科大学与中国高校及机构建立深度合作，共同设计并推出面向在校学生及企业高管的行业定制化课程与项目，进一步深化中新两国在人才培养与产业协同领域的务实合作。

拓展东北布局：沈阳卫星办事处正式启用

为深化在中国东北地区的战略布局，新加坡社科大学将于2026年3月11日在沈阳正式设立卫星办事处。该办事处将作为区域枢纽，全面支持新加坡社科大学在辽宁省（包括大连市）及周边地区的项目拓展与合作落地。

当天，新加坡社科大学还将与三家核心伙伴机构签署谅解备忘录，建立深度合作关系：

• 与沈阳化工大学：合作开发社会工作硕士课程，推动跨境学术交流、课程创新与社会工作人才培养，回应区域社会服务发展的现实需求。
• 与东北人口与社会发展研究院：聚焦积极老龄化议题，联合开展应用研究、专业发展项目与产学合作，构建基于证据的能力建设体系，服务个体与社区的可持续发展。

新加坡社科大学校长陈大荣教授表示：”中国是本校为学生创造机遇、拓展亚洲合作版图的重要战略伙伴。重庆成就学院的成立，使我们能够更紧密地携手中国西部及东北地区的高校、产业界及社区伙伴，共同提供契合现实需求的应用型实践教育。

与莱福士教育的合作，彰显了双方共同致力于培养未来型人才、支持区域专业人才成长的坚定承诺。我们将以重庆成功学院为平台，持续深化中新两国在教育与产业协同领域的务实合作。”

莱福士教育集团执行董事长黄壮龙先生表示：”我们与新加坡社科大学的合作，体现了双方对应用型实践教育的共同信念，以及对帮助学生和企业应对日益复杂且相互关联的世界的坚定承诺。

重庆作为通往中国西部的门户，同时也是重要的产业与交通枢纽，其战略地位使其成为开展沉浸式产业关联教育的理想之地。此次合作标志着双方致力于为学生与产业、学术与实践、新加坡与中国之间建造持久桥梁的长期承诺。”

重庆成就学院的成立，是新加坡社科大学深化亚洲拓展战略的重要里程碑。自2023年以来，新加坡社科大学已先后在北京、深圳、胡志明市、曼谷、吉隆坡、雅加达、马尼拉及孟买设立成就学院，逐步构建起覆盖亚洲主要城市的区域网络。

欲了解详情，请访问 www.suss.edu.sg/success-academy。

。
Hashtag: #SUSS

https://www.suss.edu.sg
https://www.linkedin.com/school/singapore-university-of-social-sciences
https://www.facebook.com/suss.sg
https://www.instagram.com/suss.sg

The issuer is solely responsible for the content of this announcement.